PL433374A1 - Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego - Google Patents

Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego

Info

Publication number
PL433374A1
PL433374A1 PL433374A PL43337420A PL433374A1 PL 433374 A1 PL433374 A1 PL 433374A1 PL 433374 A PL433374 A PL 433374A PL 43337420 A PL43337420 A PL 43337420A PL 433374 A1 PL433374 A1 PL 433374A1
Authority
PL
Poland
Prior art keywords
determining
mesenchymal
gene panel
teratogenic potential
perinatal
Prior art date
Application number
PL433374A
Other languages
English (en)
Other versions
PL241520B1 (pl
Inventor
Tomasz OŁDAK
Tomasz KOLANOWSKI
Igor STEPANIEC
Original Assignee
Polski Bank Komórek Macierzystych Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polski Bank Komórek Macierzystych Spółka Akcyjna filed Critical Polski Bank Komórek Macierzystych Spółka Akcyjna
Priority to PL433374A priority Critical patent/PL241520B1/pl
Priority to PCT/IB2021/052521 priority patent/WO2021191853A1/en
Priority to EP21726182.5A priority patent/EP4127239A1/en
Publication of PL433374A1 publication Critical patent/PL433374A1/pl
Publication of PL241520B1 publication Critical patent/PL241520B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem wynalazku jest zestaw genów zawierający co najmniej jeden panel genów wybrany z: CDKN2A, CDH20, HAND2, PDGFR-a; lub ALOX15, CDH9, DRD4, ESM1, HEY1, NKX2-5; lub FUT3, PROM1, COL2A1, FOXA1, MYO3B; lub CLDN1, CPLX2, EOMES, FOXA2, HNF1B, HNF4A, LEFTY1, POU4F1; lub TDGF1, DNMT3B, IDO1, NANOG POUF5F1, SOX2; do zastosowania przy określaniu potencjału teratogennego populacji komórek mezenchymalnych (MSC) lub populacje komórek perinatalnych.
PL433374A 2020-03-27 2020-03-27 Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego PL241520B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL433374A PL241520B1 (pl) 2020-03-27 2020-03-27 Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego
PCT/IB2021/052521 WO2021191853A1 (en) 2020-03-27 2021-03-26 The use of a gene panel to determine the teratogenic potential of mesenchymal and perinatal tissue-derived cells
EP21726182.5A EP4127239A1 (en) 2020-03-27 2021-03-26 The use of a gene panel to determine the teratogenic potential of mesenchymal and perinatal tissue-derived cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL433374A PL241520B1 (pl) 2020-03-27 2020-03-27 Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego

Publications (2)

Publication Number Publication Date
PL433374A1 true PL433374A1 (pl) 2021-10-04
PL241520B1 PL241520B1 (pl) 2022-10-17

Family

ID=75954148

Family Applications (1)

Application Number Title Priority Date Filing Date
PL433374A PL241520B1 (pl) 2020-03-27 2020-03-27 Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego

Country Status (3)

Country Link
EP (1) EP4127239A1 (pl)
PL (1) PL241520B1 (pl)
WO (1) WO2021191853A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023052820A1 (en) * 2021-09-30 2023-04-06 Polski Bank Komórek Macierzystych S.A. Expression analysis of a specific gene pool to determine whether the population of adipose tissue-derived mesenchymal cells (at-msc) selected for clinical application can undergo a transformation into neoplastic cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1761749A (zh) * 2003-03-10 2006-04-19 独立行政法人科学技术振兴机构 检测间充质干细胞的标记和采用该标记识别间充质干细胞的方法
KR100888924B1 (ko) * 2007-06-04 2009-03-16 주식회사 제이비줄기세포연구소 인간 제대혈 유래 중간엽 줄기세포와 섬유아세포 분별방법
WO2015086052A1 (en) * 2013-12-10 2015-06-18 Swiss Stem Cell Foundation Culture media for in vitro differentiation of cardiomiocytes from adipose tissue-derived mesenchymal stem cells and method to select them
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation

Also Published As

Publication number Publication date
EP4127239A1 (en) 2023-02-08
WO2021191853A1 (en) 2021-09-30
PL241520B1 (pl) 2022-10-17

Similar Documents

Publication Publication Date Title
PL433374A1 (pl) Zastosowanie panelu genów do określania potencjału teratogennego komórek mezenchymalnych i pochodzenia perinatalnego
Sobotta et al. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling
Wong et al. Mitochondrial and cytosolic sources of hydrogen peroxide in resting C2C12 myoblasts
Fischbach et al. The C-terminal domain of p53 orchestrates the interplay between non-covalent and covalent poly (ADP-ribosyl) ation of p53 by PARP1
Reiland et al. Comparative phosphoproteome profiling reveals a function of the STN8 kinase in fine-tuning of cyclic electron flow (CEF)
Van der Veen et al. Role of the ubiquitin-like protein Urm1 as a noncanonical lysine-directed protein modifier
Anastassiou On right fractional calculus
Regan et al. Extracellular superoxide dismutase and oxidant damage in osteoarthritis
Sivachandran et al. Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies
DK1280898T3 (da) Modificerede ES-celler og ES-cellespecifikt gen
GT200500233A (es) Produccion de a-beta
DK1692276T3 (da) Fremgangsmåde til induktion af udvikling og terminal differentiering af hukommelses-B-celler
Gwinner et al. Proteomics for rejection diagnosis in renal transplant patients: Where are we now?
Lehmann et al. Ubiquitination of specific mitochondrial matrix proteins
Bucan et al. LEF‐1 regulates proliferation and MMP‐7 transcription in breast cancer cells
Siegal-Gaskins et al. Biomolecular resource utilization in elementary cell-free gene circuits
Rochaix Chloroplast protein import machinery and quality control
Kleyman et al. The mechanism of action of amiloride.
Kalamvoki et al. Overexpression of the ubiquitin-specific protease 7 resulting from transfection or mutations in the ICP0 binding site accelerates rather than depresses herpes simplex virus 1 gene expression
Zhang et al. Novel insights into plasma biomarker candidates in patients with chronic mountain sickness based on proteomics
Monti et al. Modelling of SHMT1 riboregulation predicts dynamic changes of serine and glycine levels across cellular compartments
Kirino et al. Acquisition of the wobble modification in mitochondrial tRNALeu (CUN) bearing the G12300A mutation suppresses the MELAS molecular defect
Sun et al. PAD2-mediated citrullination of Fibulin-5 promotes elastogenesis
Thiel et al. Simultaneous quantitation of oxidized and reduced glutathione via LC-MS/MS to study the redox state and drug-mediated modulation in cells, worms and animal tissue
Salinger et al. Technical comment on “Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis”